TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | $799.54M |
| Gross Profit (TTM) | $658.60M |
| EBITDA | $136.45M |
| Operating Margin | 9.02% |
| Return on Equity | 100.30% |
| Return on Assets | 7.28% |
| Revenue/Share (TTM) | $5.61 |
| Book Value | $4.11 |
| Price-to-Book | 14.19 |
| Price-to-Sales (TTM) | 10.99 |
| EV/Revenue | 10.94 |
| EV/EBITDA | 62.77 |
| Quarterly Earnings Growth (YoY) | -70.60% |
| Quarterly Revenue Growth (YoY) | 70.30% |
| Shares Outstanding | $153.08M |
| Float | $135.24M |
| % Insiders | 7.47% |
| % Institutions | 74.33% |
Volatility is currently contracting
TG Therapeutics NASDAQ: TGTX Chairman, President and Chief Executive Officer Mike Weiss said the company's multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market.
Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
TG Therapeutics, Inc. remains a Buy as BRIUMVI's momentum supports a durable, growing multiple sclerosis franchise. TGTX's Q2 saw BRIUMVI revenue surge 64% YoY to $228 million, prompting 2026 guidance to $950 million, though net income was impacted by manufacturing investments. Subcutaneous BRIUMVI, with Phase 3 data expected late 2026 or early 2027, could expand the addressable market and drive future gross margin tailwinds.
TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TG Therapeutics NASDAQ: TGTX reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment persistence.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TGTX and any ticker you trade — then tracks every position and per-strategy win rate.
